FR09C0041I2 - - Google Patents

Info

Publication number
FR09C0041I2
FR09C0041I2 FR09C0041C FR09C0041C FR09C0041I2 FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2 FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2
Authority
FR
France
Prior art keywords
pain
inflammatory
chronic
analgesics
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0041C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of FR09C0041I1 publication Critical patent/FR09C0041I1/fr
Application granted granted Critical
Publication of FR09C0041I2 publication Critical patent/FR09C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR09C0041C 2001-03-20 2009-09-07 Active FR09C0041I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01106891A EP1243262B1 (de) 2001-03-20 2001-03-20 Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PCT/EP2002/003034 WO2002074784A2 (en) 2001-03-20 2002-03-19 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
EP02727437A EP1373300B1 (de) 2001-03-20 2002-03-19 Verwendung einer peptidartigen verbindung zur behandlung von neuropathischen entzündlichen schmerzerscheinungen

Publications (2)

Publication Number Publication Date
FR09C0041I1 FR09C0041I1 (de) 2009-10-30
FR09C0041I2 true FR09C0041I2 (de) 2010-01-22

Family

ID=8176844

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0041C Active FR09C0041I2 (de) 2001-03-20 2009-09-07

Country Status (30)

Country Link
US (3) US6803481B2 (de)
EP (2) EP1243262B1 (de)
JP (1) JP4955906B2 (de)
KR (1) KR100773100B1 (de)
CN (2) CN100415225C (de)
AT (2) ATE327744T1 (de)
AU (1) AU2002257681C1 (de)
BR (1) BR0205823A (de)
CA (1) CA2419397C (de)
CY (3) CY1105533T1 (de)
CZ (1) CZ20032763A3 (de)
DE (3) DE60120104T2 (de)
DK (2) DK1243262T3 (de)
EA (1) EA007532B1 (de)
ES (2) ES2262567T3 (de)
FR (1) FR09C0041I2 (de)
HU (1) HUP0303600A3 (de)
IL (2) IL154087A0 (de)
LU (1) LU91590I2 (de)
MX (1) MXPA03008467A (de)
NL (1) NL300399I1 (de)
NO (1) NO20033629L (de)
NZ (1) NZ523865A (de)
PL (1) PL216213B1 (de)
PT (2) PT1243262E (de)
SI (2) SI1373300T1 (de)
SK (1) SK287539B6 (de)
UA (1) UA82645C2 (de)
WO (1) WO2002074784A2 (de)
ZA (1) ZA200300858B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695703B1 (de) * 2000-08-25 2010-08-11 Research Corporation Technologies, Inc. Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
EP1243262B1 (de) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
WO2005053667A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006021412A2 (en) 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
AR057643A1 (es) 2005-01-28 2007-12-12 Sanol Arznei Schwarz Gmbh Lacosamida para terapia adjunta
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
AU2007256352A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2011037833A2 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (de) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
JP3827324B2 (ja) * 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
ES2133807T3 (es) 1994-10-05 1999-09-16 Darwin Discovery Ltd Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (de) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) * 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
JP2001521927A (ja) 1997-10-31 2001-11-13 ビーエーエスエフ アクチェンゲゼルシャフト アミド側鎖を有する新規のカルボン酸誘導体、その製造およびエンドセリン受容体アンタゴニストとしての使用
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
ES2295048T3 (es) 1999-09-03 2008-04-16 Actelion Pharmaceuticals Ltd. Bis-sulfonamidas.
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
WO2002013766A2 (en) * 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
EP1695703B1 (de) * 2000-08-25 2010-08-11 Research Corporation Technologies, Inc. Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
EP1243262B1 (de) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
EP1379523B1 (de) 2001-03-27 2005-07-27 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
WO2002088664A2 (en) 2001-04-26 2002-11-07 Bristol-Myers Squibb Company Control of compactability through crystallization
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US7485622B2 (en) 2002-11-18 2009-02-03 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
CA2511385A1 (en) 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
US20040209960A1 (en) 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
JP2006515326A (ja) 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (de) 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
WO2005053667A1 (en) 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (de) 2003-12-05 2005-06-15 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Status Epilepticus und ähnlicher Zustände
EP1579858A1 (de) 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006021412A2 (en) 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (de) 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (de) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 zur Co-Therapie der Schizophrenie
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie

Also Published As

Publication number Publication date
FR09C0041I1 (de) 2009-10-30
ES2262567T3 (es) 2006-12-01
ES2326627T3 (es) 2009-10-16
ATE327744T1 (de) 2006-06-15
DK1243262T3 (da) 2006-10-02
CA2419397C (en) 2009-09-15
US6803481B2 (en) 2004-10-12
DE60232407D1 (de) 2009-07-02
JP2004524340A (ja) 2004-08-12
NO20033629D0 (no) 2003-08-15
KR20040004369A (ko) 2004-01-13
DE60120104T2 (de) 2006-09-21
ATE431833T1 (de) 2009-06-15
NL300399I1 (en) 2009-10-01
CY2009013I1 (el) 2012-01-25
SK12832003A3 (sk) 2004-02-03
DK1373300T3 (da) 2009-08-31
EP1373300A2 (de) 2004-01-02
KR100773100B1 (ko) 2007-11-02
CN101332292A (zh) 2008-12-31
ZA200300858B (en) 2003-07-09
HUP0303600A2 (hu) 2004-03-01
NO20033629L (no) 2003-08-15
LU91590I2 (fr) 2009-10-05
SI1373300T1 (sl) 2009-10-31
US20050085423A1 (en) 2005-04-21
EA007532B1 (ru) 2006-10-27
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
EP1243262B1 (de) 2006-05-31
BR0205823A (pt) 2003-10-21
NZ523865A (en) 2004-12-24
HK1058368A1 (en) 2004-05-14
CN101332292B (zh) 2012-06-20
US20070054962A1 (en) 2007-03-08
HUP0303600A3 (en) 2011-11-28
DE122009000053I1 (de) 2010-05-27
PT1243262E (pt) 2006-10-31
CN100415225C (zh) 2008-09-03
CY1109308T1 (el) 2012-01-25
WO2002074784A3 (en) 2002-11-21
CN1498103A (zh) 2004-05-19
EA200300932A1 (ru) 2004-04-29
AU2002257681B2 (en) 2007-06-07
WO2002074784A2 (en) 2002-09-26
CZ20032763A3 (cs) 2004-01-14
IL154087A (en) 2010-05-17
JP4955906B2 (ja) 2012-06-20
US20030171300A1 (en) 2003-09-11
DE60120104D1 (de) 2006-07-06
CY2009013I2 (el) 2012-01-25
PL362985A1 (en) 2004-11-15
AU2002257681C1 (en) 2008-02-21
US8053476B2 (en) 2011-11-08
CY1105533T1 (el) 2010-07-28
EP1373300B1 (de) 2009-05-20
SK287539B6 (sk) 2011-01-04
SI21170A (sl) 2003-10-31
MXPA03008467A (es) 2003-12-08
IL154087A0 (en) 2003-07-31
EP1243262A1 (de) 2002-09-25
AU2002257681A2 (en) 2002-10-03
PT1373300E (pt) 2009-07-22
CA2419397A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
FR09C0041I1 (de)
MXPA04001891A (es) Inhibidores policiclicos de guanina fosfodiesterasa v.
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
MXPA03011546A (es) Formulacion farmaceutica.
EA200400410A1 (ru) Комбинация нспвлс и ингибитора pde-4
EP1900362A3 (de) Alpha-Aminoamid-Derivate zur Behandlung von Suchtstörungen
HUP0301828A3 (en) Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
GB0303319D0 (en) Organic compounds
NL1019899A1 (nl) Verwijdering van onzuiverheden uit koolwaterstofstromen.
GB9925016D0 (en) Binding surface
BR0008608A (pt) Derivados de pirazol-3-ona
WO2002070457A8 (en) Inhibitor of monoamine uptake
EP1498501A4 (de) Verfahren zur herstellung von martensitischem nichtrostendem stahl
WO2004062598A3 (en) Anti-inflammatory and anti-thrombotic compounds and their compositions
FR2875510B1 (fr) Procede de traitement pour inhiber la corrosion de voute de pipes utilises dans l'industrie petroliere
EA200401339A1 (ru) Нитрозированные имидазопиридины
WO2003005956A3 (en) A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity
WO2002064742A3 (en) Compounds effecting neuron remodeling and assays for same
FR2818292B1 (fr) Chambre de reaction metallique anti-corrosion de procede cvd ou rtp
FR2888519B1 (fr) Procede de traitement, par plasma, d'effluents gazeux
HK1064662A (en) Compounds for the treatment of inflammatory disorders